To develop new therapeutic strategies that target metabolic alterations in combination with ICI regimens for NSCLC with LKB1 and/or KEAP1 inactivation, further extensive analyses on a larger scale will be necessary. Here, KEAP1 is linked to non-small cell lung carcinoma.